A naukri.com initiative
Bioengineer
15h
65
Image Credit: Bioengineer
Dana-Farber Genomic Score Forecasts Progression Risk in Multiple Myeloma
- A novel genomic risk assessment tool, the MM-like score, has been developed to predict progression risk in multiple myeloma (MM).
- Multiple myeloma is a blood cancer that often starts with asymptomatic phases like monoclonal gammopathy and smoldering myeloma.
- The MM-like score uses whole-genome sequencing data to track the evolution of MM from early stages to malignancy.
- It provides a dynamic risk estimation based on genetic mutations, surpassing traditional clinical parameters.
- Study highlights the importance of genomic insights in predicting disease progression and individualized treatment planning.
- Genomic data analysis from over 1,000 patients revealed genetic alterations occurring years before clinical diagnosis.
- The MM-like score correlates with disease advancement and could serve as a biomarker for real-time monitoring and risk prediction.
- Future goals include making the MM-like score available as a non-invasive liquid biopsy for more accessible disease monitoring.
- This innovative approach could lead to early therapeutic interventions and improved outcomes for high-risk patients.
- Deep whole-genome sequencing has allowed for the detection of crucial genetic events, reshaping understanding of multiple myeloma evolution.
Read Full Article
3 Likes
For uninterrupted reading, download the app